MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial

L V Magnussen; P E Andersen; Alejandro Rafael Diaz; J Ostojic; K. Højlund; D. M. Hougaard; Anders Nymark Christensen; T. L. Nielsen; M Andersen

doi:10.1530/EJE-17-0071

MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial

L V Magnussen
, P E Andersen
, Alejandro Rafael Diaz
, J Ostojic
, K. Højlund
, D. M. Hougaard
, Anders Nymark Christensen
, T. L. Nielsen
, M Andersen

University of Southern Denmark
University of Novi Sad
Statens Serum Institut

Research output: Contribution to journal › Journal article › Research › peer-review

442 Downloads (Orbit)

Abstract

Men with type 2 diabetes mellitus (T2D) often have lowered testosterone levels and an increased risk of cardiovascular disease (CVD). Ectopic fat increases the risk of CVD, whereas subcutaneous gluteofemoral fat protects against CVD and has a beneficial adipokine-secreting profile. Testosterone replacement therapy (TRT) may reduce the content of ectopic fat and improve the adipokine profile in men with T2D. A randomized, double-blinded, placebo-controlled study in 39 men aged 50-70 years with T2D and bioavailable testosterone levels

Original language	English
Journal	European Journal of Endocrinology
Volume	177
Issue number	2
Pages (from-to)	157-168
ISSN	0804-4643
DOIs	https://doi.org/10.1530/EJE-17-0071
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1530/EJE-17-0071

MR spectroscopy of hepatic fatFinal published version, 1.2 MB

OpenUrl availability

Check availability in DTU Findit

Fingerprint

Dive into the research topics of 'MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this

Magnussen, L. V., Andersen, P. E., Diaz, A. R., Ostojic, J., Højlund, K., Hougaard, D. M., Christensen, A. N., Nielsen, T. L., & Andersen, M. (2017). MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial. European Journal of Endocrinology, 177(2), 157-168. https://doi.org/10.1530/EJE-17-0071

@article{6170d8f6dcb6497d95fd395e1411597d,

title = "MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial",

abstract = "Men with type 2 diabetes mellitus (T2D) often have lowered testosterone levels and an increased risk of cardiovascular disease (CVD). Ectopic fat increases the risk of CVD, whereas subcutaneous gluteofemoral fat protects against CVD and has a beneficial adipokine-secreting profile. Testosterone replacement therapy (TRT) may reduce the content of ectopic fat and improve the adipokine profile in men with T2D. A randomized, double-blinded, placebo-controlled study in 39 men aged 50-70 years with T2D and bioavailable testosterone levels ",

author = "Magnussen, \{L V\} and Andersen, \{P E\} and Diaz, \{Alejandro Rafael\} and J Ostojic and K. H{\o}jlund and Hougaard, \{D. M.\} and Christensen, \{Anders Nymark\} and Nielsen, \{T. L.\} and M Andersen",

year = "2017",

doi = "10.1530/EJE-17-0071",

language = "English",

volume = "177",

pages = "157--168",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "Oxford University Press",

number = "2",

}

Magnussen, LV, Andersen, PE, Diaz, AR, Ostojic, J, Højlund, K, Hougaard, DM, Christensen, AN, Nielsen, TL & Andersen, M 2017, 'MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial', European Journal of Endocrinology, vol. 177, no. 2, pp. 157-168. https://doi.org/10.1530/EJE-17-0071

MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial. / Magnussen, L V; Andersen, P E; Diaz, Alejandro Rafael et al.
In: European Journal of Endocrinology, Vol. 177, No. 2, 2017, p. 157-168.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial

T2 - A randomized, double-blinded, placebo-controlled trial

AU - Magnussen, L V

AU - Andersen, P E

AU - Diaz, Alejandro Rafael

AU - Ostojic, J

AU - Højlund, K.

AU - Hougaard, D. M.

AU - Christensen, Anders Nymark

AU - Nielsen, T. L.

AU - Andersen, M

PY - 2017

Y1 - 2017

N2 - Men with type 2 diabetes mellitus (T2D) often have lowered testosterone levels and an increased risk of cardiovascular disease (CVD). Ectopic fat increases the risk of CVD, whereas subcutaneous gluteofemoral fat protects against CVD and has a beneficial adipokine-secreting profile. Testosterone replacement therapy (TRT) may reduce the content of ectopic fat and improve the adipokine profile in men with T2D. A randomized, double-blinded, placebo-controlled study in 39 men aged 50-70 years with T2D and bioavailable testosterone levels

AB - Men with type 2 diabetes mellitus (T2D) often have lowered testosterone levels and an increased risk of cardiovascular disease (CVD). Ectopic fat increases the risk of CVD, whereas subcutaneous gluteofemoral fat protects against CVD and has a beneficial adipokine-secreting profile. Testosterone replacement therapy (TRT) may reduce the content of ectopic fat and improve the adipokine profile in men with T2D. A randomized, double-blinded, placebo-controlled study in 39 men aged 50-70 years with T2D and bioavailable testosterone levels

U2 - 10.1530/EJE-17-0071

DO - 10.1530/EJE-17-0071

M3 - Journal article

C2 - 28522646

SN - 0804-4643

VL - 177

SP - 157

EP - 168

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 2

ER -

Magnussen LV, Andersen PE, Diaz AR, Ostojic J, Højlund K, Hougaard DM et al. MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial. European Journal of Endocrinology. 2017;177(2):157-168. doi: 10.1530/EJE-17-0071